In order to improve the professional skills of the company's marketing staff, on May 6, Hongqi Pharmaceutical invited the director of Beijing Chest Hospital Lu Yu to the company for anti-tuberculosis drug-related product knowledge training. The main contents include the development of anti-tuberculosis drugs and the pharmacology of first-line anti-tuberculosis drugs. Product knowledge such as medicinal effects. Nearly 50 key employees of the company's executives, market access department, chief engineering office, pharmacovigilance department, R&D, quality, and marketing departments all actively participated in this professional training.

Teacher Lu Yu introduced in detail the international and domestic status of tuberculosis treatment, the pharmacological effects and clinical precautions of the main first-line tuberculosis drugs, and proposed the current international and domestic research and development needs for new anti-tuberculosis drugs, prompting tuberculosis pharmaceutical companies to collaborate with multi-professional talents and society Forces from all walks of life actively promote the research and development of new anti-tuberculosis drugs, and pay attention to the research on the efficacy of existing drugs.

Finally, I hope Hongqi Pharmaceuticals, as a leading company in the field of anti-tuberculosis drugs, can actively assume more social responsibilities and make unremitting efforts for the goal of ending tuberculosis.